DGKζ-IN-4 is a selective inhibitor of DGKζ active in the nanomolar range and proposed as a potential therapeutic agent for cancer associated with immune cell activation or resistant to anti-PD-1 antibody/anti-PD-L1 antibody therapy (Watanabe et al. Patent WO2022114164). Here, CD274 is linked to cancer.